Press Releases

CHILLICOTHE, Ohio, Dec. 16, 2019 /PRNewswire/ -- Petland learned today that the Centers for Disease Control (CDC) will be releasing an update tomorrow in regards to human cases of Campy

NEW YORK and TOKYO, Dec. 16, 2019 /PRNewswire/ -- Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for XTANDI&re

PALO ALTO, Calif., Dec. 16, 2019 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a late stage clinical biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has initiated submission of a New Drug Application (NDA) for Lonafarnib for the treatment of

STAINES-UPON-THAMES, United Kingdom, Dec. 16, 2019 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a global biopharmaceutical company, today confirmed enrollmen

NEW YORK, Dec. 16, 2019 /PRNewswire/ -- Spheryx announces the publication of an article entitled "The role of the medium in the effective-sphere interpretation of holographic particle characterization data" in the peer-reviewed journal, Soft Matter, which can be found at

INDIANAPOLIS, Dec. 16, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today announced a 15 percent increase in its quarterly dividend. The dividend for the first quarter of 2020 will be $0.74 per share on outstanding common stock. This raises the annual indicated rate to $2.9

SALT LAKE CITY, Dec. 16, 2019 /PRNewswire/ -- Destiny Wholf, an Ohio-based nurse practitioner, received the inaugural $10,000 Dale Brunken Memorial Student Loan Payment Award. The award is named for the man who founded MGIS fifty years ago to serve

SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that data supporting the novel mechanism of action for the investigational agent HT

SAN FRANCISCO, Dec. 16, 2019 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NASH) and other serious metabolic disorders, today announced that it has completed enrollment in the Phase 2a BALANCED study of AKR-001, a novel FGF21 anal

SAN DIEGO, Dec. 16, 2019 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, announced today that it plans to offer shares of its common stock in an underwritten public offering.  In connection with the offering, the Company intends to grant the underwriters a 30-day option to purch